EDWARDS LIFESCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Edwards Lifesciences Corp. - EW
EDWARDS LIFESCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Edwards Lifesciences Corp. - EW
NEW ORLEANS, LA--(Marketwired - Sep 19, 2013) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 18, 2013 to file lead plaintiff applications in a securities class action lawsuit against Edwards Lifesciences Corp. (NYSE: EW), if they purchased the Company's securities during the period between April 25, 2012 and April 23, 2013, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you purchased shares of Edwards Lifesciences and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com) or KSF Partner Melinda Nicholson (melinda.nicholson@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 18, 2013.
About the Lawsuit
Edwards Lifesciences and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.
These false statements and omissions included, in part, that: (i) adoption of the Company's Edwards SAPIEN transcatheter aortic heart valve, including the related transfemoral and transapical delivery methods, was weaker than the Company claimed, due to concerns among physicians over the risks and complexity of the procedure for implanting the valve; (ii) Edwards Lifesciences' outlook for sales and earnings per share was significantly weaker than the optimistic guidance defendants offered to investors; and (iii) as a result, defendants lacked a reasonable basis for the statements made concerning the Company's operations, forecasts and outlook.
About Kahn Swick & Foti, LLC
To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.